The COVID-19 pandemic has underscored the transformational potential of nanomedicines, igniting a surge of interest in the Nano-Drug Delivery System (NDDS). NDDS, serving as carriers of potent therapeutic agents, have the exceptional capacity to convert scientific theories into actual, safe, and effective medical solutions. Nevertheless, the transition of these innovations from the research lab to the clinical application is not straightforward. It is typically a complex process filled with trials and tribulations that require significant time and resources. Yet, the advent of automation, artificial intelligence (AI), and machine learning (ML) shines a beacon of hope in this labyrinth, paving the way for a smoother NDDS design journey. These promising yet relatively untapped tools are at the heart of our lab’s work. 

What we do

Self-Driving Labs (Nano-MAP): The design and development of nanomedicines represent a pivotal challenge in the pharmaceutical industry. The complexity is greater in comparison to conventional pharmaceutical forms like tablets and capsules. To address this, we propose a game-changing solution: NanoMAP – a self-driving laboratory. This ground-breaking platform leverages the strength of AI, ML, and high-throughput experimentation to streamline the design process and expedite the evolution of nanomedicines. NanoMAP has the potential to propel nanomedicine into a faster development track, shaping its future trajectory.

Self Nano-emulsifying Drug Delivery System (SNEDDS): Our team is exploring the possibilities offered by SNEDDS for highly lipophilic drugs, such as cannabidiol (CBD). These homogeneous mixtures, conveniently encapsulated in gel capsules, introduce an innovative method for drug absorption and metabolism. Our ongoing research focuses on developing SNEDDS formulations of CBD that disperse swiftly in biorelevant media using a digestion-resistant surfactant. After extensive in vitro testing, prospective formulations have undergone rigorous in vivo evaluation, offering invaluable insights into CBD’s pharmacokinetic profiles following oral administration in healthy Sprague-Dawley rats.

Representative publications